An observational study in Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma and COVID-19, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. Recruiting at 15 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto — 5 open to participants now, 7 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Gruppo Italiano Malattie EMatologiche dell'Adulto.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2023, is one of 10 observational ones, and was the 16th registered.
2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →5 of the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto are open now, in 1 country. Recruiting first, the newest first:
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
Gruppo Italiano Malattie EMatologiche dell'Adulto
Ages 18+
By country, each count listing its studies:
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6
First in 2007; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 954 is above the median of 148 across 216 observational studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 44 across the 8 interventional studies, 203 across the 10 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gruppo Italiano Malattie EMatologiche dell'Adulto is the lead sponsor of 135 studies on the registry; 36 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.
This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients.
All CLL or indolent B-cell NHL patients (follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma) who received first COVID-19 prophylaxis dose with Tixagevimab and Cilgavimab according to AIFA indication between March 2022 and October 2022 will be included in the study.
Each patient will be followed for a maximum of 12 months from the first COVID-19 prophylaxis dose.
Patients with CLL or indolent B-NHL (follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma) who received the Tixagevimab and Cilgavimab as per Agenzia Italiana del Farmaco (AIFA) indications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assess the percentage of patients who develop severe COVID-19 infection
Evaluation of prophylaxis efficacy in terms of percentage of patients with CLL or indolent B-NHL who develop severe COVID-19 infection, defined as COVID-19-related hospitalization or COVID -19 related death
Time frame: at 12 months
Started Sep 2023 (actual). Primary completion is estimated for Sep 2024, 12 months after the start.
Of 70 non-industry observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30. This study's planned 12 months is below that.
Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Lymphocytic, Chronic, B-Cell →
Gruppo Italiano Malattie EMatologiche dell'Adulto →